Head and neck cancers (HNC) are rare form of cancers that arise from various locations in the oral and nasal cavities. Both smoking and HPV infection increase the risk of developing these cancers. As a result, the number of patients has doubled for the last 10 years. Head and neck cancers are commonly treated with surgery and radiation, but tumor recurrence is very high putting serious burden on the patients. As with most cancer therapies, head and neck cancer patients suffer from various diseases caused by cancer therapy. Oral mucositis is a painful inflammatory disease that occurs in most head and neck cancer patients receiving radiation therapy. GlycoMira is developing therapeutics to reduce oral mucositis that will enhance the outcomes of the cancer therapy. We approach this challenge with synthetic glycosaminoglycan technology and our drug candidate GM-1111 provides powerful anti-inflammatory effects.
NIH Grant Awards
GlycoMira received Small Business Innovation Research grant awards
Pulsipher A, Savage JR, Kennedy TP, Gupta K, Cuiffo BG, Sonis ST, et al. (2021) GM-1111 reduces radiation-induced oral mucositis in mice by targeting pattern recognition receptor-mediated inflammatory signaling. PLoS ONE 16(3): e0249343. https://doi.org/10.1371/journal.pone.0249343